



## GENMAB ACHIEVES MILESTONE IN ARZERRA™ COLLABORATION

*Summary: Genmab will receive a milestone payment of approximately DKK 87 million from GSK for the European Commission's conditional marketing authorization for Arzerra™.*

**Copenhagen, Denmark; April 19, 2010** – Genmab A/S (OMX: GEN) announced today it has reached a milestone for Arzerra™ (ofatumumab) under the terms of its collaboration with GlaxoSmithKline (GSK). A milestone payment of approximately DKK 87 million (approximately USD 16 million) was triggered by the European Commission's granting of a conditional marketing authorization for ofatumumab for the treatment of refractory chronic lymphocytic leukemia (CLL).

“This milestone marks an important achievement; the first Genmab antibody to reach the market in Europe,” said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.

Ofatumumab is a novel human monoclonal antibody with a unique mode of action. It targets a unique part of the CD20 molecule encompassing an epitope in the small loop. The CD20 molecule is a key target in CLL therapy, because it is expressed in most B cell malignancies.

### **About Genmab A/S**

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab's world class discovery and development teams are using cutting-edge technology to create and develop products to address unmet medical needs. Our primary goal is to improve the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit [www.genmab.com](http://www.genmab.com).

*This Stock Exchange Release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the section “Risk Management” in Genmab's Annual Report, which is available on [www.genmab.com](http://www.genmab.com). Genmab does not undertake any obligation to update or revise forward looking statements in this Stock Exchange Release nor to confirm such statements in relation to actual results, unless required by law.*

## **GENMAB ACHIEVES MILESTONE IN ARZERRA™ COLLABORATION**

Genmab®; the Y-shaped Genmab logo®; HuMax®; HuMax-CD20®; HuMax-EGFr™; HuMax-IL8™; HuMax-TAC™; HuMax-HepC™; HuMax-CD38™; HuMax-CD32b™; HuMax-TF™; HuMax-Her2™; HuMax-VEGF™, HuMax-Wnt and UniBody® are all trademarks of Genmab A/S. Arzerra™ is a trademark of GlaxoSmithKline.

Contact: Helle Husted, Vice President, Investor Relations  
T: +45 33 44 77 30; M: +45 25 27 47 13; E: h.husted@genmab.com

###